Who Paid My Doc
Phase 1 Drug Interaction (AKA IM042-002) (EOE)
Research payments
$1,260,749
Through program year 2024, $1,260,749 in research payments was reported against Phase 1 Drug Interaction (AKA IM042-002) (EOE), across 69 payments.
- Paid by (largest first)
- Celgene Corporation; E.R. Squibb & Sons, L.L.C.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $753,136 | 22 |
| 2023 | Research | $430,230 | 25 |
| 2022 | Research | $77,383 | 22 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Siddharth Mathur Crystal River, FL Named on 5 payments
- Salam Zakko Bristol, CT Named on 4 payments
- Bassel Kisso Tucson, AZ Named on 4 payments
- Rami El Abiad Dubuque, IA Named on 4 payments
- Lance Rudolph Albuquerque, NM Named on 4 payments
- Carlos Ramos Miami, FL Named on 4 payments
- Donald McNeil Louisville, KY Named on 3 payments
- Nicholas Karyotakis Los Angeles, CA Named on 3 payments
- Jonathan Rosenberg Lake Bluff, IL Named on 3 payments
- David Leiman Durham, NC Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.